Navigation Links
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Date:2/20/2013

RIDGEFIELD, Conn., Feb. 20, 2013 /PRNewswire/ -- New findings from two double-blind, randomized trials, RE-MEDYSM and RE-SONATE®, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE)*. The results were published today in the New England Journal of Medicine.

VTE is the third most common cardiovascular disorder after heart disease and stroke, and consists of two related conditions caused by blood clots: deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT is when a blood clot develops in the deep veins of the leg or pelvis. The clot, or part of it, can break off from the site where it formed and travel through the veins (embolism). A PE can occur if the clot lodges in the arteries of the lungs.

There are an estimated 900,000 VTE events per year in the U.S., approximately one-third of which result in death from PE. Further, roughly one-third of people with VTE will have a recurrence within 10 years. The standard of care for patients with VTE is anticoagulation.

RE-MEDY demonstrated that treatment with dabigatran 150 mg twice daily was non-inferior to warfarin (p=0.01) in preventing recurrent VTE, including VTE-related death. RE-SONATE demonstrated dabigatran was superior to placebo for the prevention of first recurrent or fatal VTE with a risk reduction of 92 percent during the treatment period (p<0.001). Lower event rates were reported across all secondary efficacy endpoints for dabigatran over placebo.

"Patients who suffer one VTE event are at increased risk of suffering another, with the risk accumulating over time," said Sam Schulman , M.D., Ph.D., FRCPC(C), lead study author and professor, Department of Medicine, McMaster University, Ontario, Canada. "We are encouraged to see that the RE-MEDY and RE-SONATE trials met their endpoints and we will continue to study the safety, efficacy and p
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Concord Medical Services Holdings Limited ... ), a leading specialty hospital management solution provider and ... imaging centers in China , today ... Directors declared a special cash dividend of US$0.30 per ... on the Company,s outstanding ordinary shares. The total expense ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
(Date:7/28/2014)... CARLSBAD, Calif. , July 28, 2014  Isis ... following webcast:What:Isis Pharmaceuticals, Second Quarter 2014 Financial Results and ... / 7:30 a.m. PTWhere: www.isispharm.com How:Live on the ... you are unable to participate during the live event, ... a limited time at www.isispharm.com . ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... PRINCETON, N.J., May 27 Impliant, Inc., a ... today announced,that it has received FDA approval to ... its TOPS(TM) System, a Total Posterior Arthroplasty,device designed ... arthrosis,and spondylolisthesis., (Logo: http://www.newscom.com/cgi-bin/prnh/20080527/NETU060LOGO ), ...
... Only Treatment for Hunter Syndrome Now Approved in 40 Countries ... ... Worldwide, BASINGSTOKE, England and CAMBRIDGE, Massachusetts, May 27, Shire ... that ELAPRASE(R),(idursulfase), a human enzyme replacement therapy for the treatment ...
Cached Medicine Technology:Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System 2Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System 3Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 2Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 3Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 4Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil 5
(Date:7/28/2014)... (PRWEB) July 29, 2014 ... in Situ Hybridization, Digital pathology & Workflow, ... Lymphoma, Prostate Cancer, Non Small Cell Lung ... End-Users (Hospitals, Pharmaceutical companies, Research Laboratories, Contract ... (The Americas, Europe, BRIC, Japan & RoW) ...
(Date:7/28/2014)... A lush green lawn offers the perfect setting for ... summer heat, lack of rain, foot traffic, and insects can ... The Grounds Guys recommends these suggestions for nurturing your summer ... week and set the height on the lawn mower about ... from heat and allows roots to retain water and grow ...
(Date:7/28/2014)... MI (PRWEB) July 28, 2014 UHY ... introduces the latest edition of UHY International Business – ... by our members, on the most current business challenges ... the world. Issue 29 covers the following topics:, ... Which industry sectors will thrive over the next five ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Dawn ... including sales, finance, and music. This experience has ... the direction of psychology. Her professional counseling ( ... and court-ordered treatment for offenders in domestic violence. ... Dawning Phoenix, LLC, she enjoys counseling individuals and ...
(Date:7/28/2014)... A revised version of a surgical procedure to treat ... more than 90 percent of the time in patients ... the MGH Division of Plastic and Reconstructive Surgery report ... the non-endoscopic procedure all of whom had headaches ... symptom relief a year later. The team,s paper ...
Breaking Medicine News(10 mins):Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2Health News:Non-endoscopic migraine surgery provides significant symptom relief 2
... , RIDGEFIELD, Conn., Sept. 24 Few people ... understanding of what it feels like to live with diabetes every ... That,s about to change. In recognition of World Diabetes Day on ... is challenging people living with diabetes to visually reveal its impact ...
... , , , ... simple task, especially when your child has a chronic health condition ... Frost, has partnered with nonprofit family health organization, Allergy & Asthma ... launch Ti m e 2 Talk Asthma , ...
... (September 24, 2009) Leon Reijmers, PhD, assistant professor ... Boston, is one of 55 recipients of the National ... investigating the way memories are stored in the brain, ... storage. Groups of neurons that participate in long-term ...
... recession, survey finds , THURSDAY, Sept. 24 (HealthDay News) -- ... for many Americans, according to a new survey that found ... a variety of body aches. , An American Pain Foundation ... those who suffered acute back pain or other minor muscle ...
... , NEW YORK, Sept. 24 An Ohio woman, 40-year-old Carolyn ... she,s due to deliver the first week in October is not hers. Several ... to his biological parents. The name of the clinic is not being released ... The AFA is issuing the following statements regarding the matter: , , ...
... , , ROCHESTER, ... Mayo Clinic and Microsoft Corp.,s shared vision to help families take ... to Mayo Clinic Health Manager , a free ... health. People with conditions such as hypertension and high cholesterol will ...
Cached Medicine News:Health News:Video: Making Sense of Diabetes Video Contest Asks 'What Does Diabetes Taste, Smell or Sound Like to You?' 2Health News:Video: Making Sense of Diabetes Video Contest Asks 'What Does Diabetes Taste, Smell or Sound Like to You?' 3Health News:Video: Making Sense of Diabetes Video Contest Asks 'What Does Diabetes Taste, Smell or Sound Like to You?' 4Health News:Parenting Expert and Family Advocate Jo Frost and Allergy & Asthma Network Mothers of Asthmatics (AANMA) Launch Time 2 Talk Asthma 2Health News:Parenting Expert and Family Advocate Jo Frost and Allergy & Asthma Network Mothers of Asthmatics (AANMA) Launch Time 2 Talk Asthma 3Health News:Neuroscientist from Tufts School of Medicine named NIH New Innovator 2Health News:Bad Economy Really Hurts Some Folks 2Health News:The American Fertility Association Responds to Alleged Embryo Mix-Up Case in Ohio 2Health News:The American Fertility Association Responds to Alleged Embryo Mix-Up Case in Ohio 3Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 2Health News:Mayo Clinic Health Manager Now Includes Features for People Managing Hypertension and High Cholesterol 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: